Celgene Corporation (CELG) Position Boosted by YHB Investment Advisors Inc.
YHB Investment Advisors Inc. increased its stake in shares of Celgene Corporation (NASDAQ:CELG) by 3.1% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 73,675 shares of the biopharmaceutical company’s stock after buying an additional 2,237 shares during the period. Celgene Corporation makes up approximately 1.8% of YHB Investment Advisors Inc.’s holdings, making the stock its 15th largest position. YHB Investment Advisors Inc.’s holdings in Celgene Corporation were worth $9,139,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of CELG. Diversified Trust Co boosted its stake in Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 9 shares in the last quarter. South Texas Money Management Ltd. boosted its stake in Celgene Corporation by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 15 shares in the last quarter. Cadence Bank NA boosted its stake in Celgene Corporation by 0.6% in the first quarter. Cadence Bank NA now owns 7,496 shares of the biopharmaceutical company’s stock valued at $933,000 after buying an additional 45 shares in the last quarter. Washington Trust Bank boosted its stake in Celgene Corporation by 1.3% in the first quarter. Washington Trust Bank now owns 3,613 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 46 shares in the last quarter. Finally, Beach Investment Management LLC. boosted its stake in Celgene Corporation by 0.8% in the first quarter. Beach Investment Management LLC. now owns 6,200 shares of the biopharmaceutical company’s stock valued at $771,000 after buying an additional 50 shares in the last quarter. 79.43% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Celgene Corporation (NASDAQ CELG) traded up 2.29% during midday trading on Monday, reaching $132.65. 843,204 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $133.39 and a 200-day moving average of $125.39. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00. The company has a market capitalization of $103.78 billion, a PE ratio of 41.08 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter in the prior year, the firm posted $1.44 earnings per share. The business’s quarterly revenue was up 18.7% on a year-over-year basis. Equities analysts expect that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/28/celgene-corporation-celg-position-boosted-by-yhb-investment-advisors-inc.html.
Several research firms recently issued reports on CELG. Jefferies Group LLC set a $154.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a report on Saturday, May 13th. BTIG Research cut shares of Celgene Corporation from a “buy” rating to a “neutral” rating and upped their price target for the company from $96.93 to $131.70 in a report on Friday, June 30th. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price target on the stock in a report on Thursday, August 10th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene Corporation in a report on Monday. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a report on Monday, May 22nd. One analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. Celgene Corporation has a consensus rating of “Buy” and an average target price of $147.44.
In related news, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the sale, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now directly owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. Insiders have sold 253,761 shares of company stock valued at $33,792,445 in the last ninety days. 0.95% of the stock is currently owned by insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.